A1 Refereed original research article in a scientific journal
Genome-Wide Association Study of Prostate Cancer–Specific Survival
Authors: Robert Szulkin, Robert Karlsson, Thomas Whitington, Markus Aly, Henrik Gronberg, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G. Giles, Melissa C. Southey, Liesel M. FitzGerald, Brian E. Henderson, Fredrick R. Schumacher, Christopher A. Haiman, Csilla Sipeky, TeuvoL.J.Tammela, Børge G.Nordestgaard,Timothy J.Key, Ruth C.Travis, David E. Neal, Jenny L. Donovan, Freddie C. Hamdy, Paul D.P. Pharoah, Nora Pashayan, Kay-Tee Khaw, Janet L. Stanford, Stephen N.Thibodeau, Shannon K. McDonnell, Daniel J. Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S. Kibel, Cezary Cybulski, Jan Lubinski,Wojciech Kluzniak, Lisa Cannon-Albright, Hermann Brenner, Volker Herrmann, Bernd Holleczek, Jong Y. Park, Thomas A. Sellers, Hui-Yi Lim, Chavdar Slavov, Radka P. Kaneva, Vanio I. Mitev, Amanda Spurdle, Manuel R. Teixeira ,Paula Paulo, Sofia Maia, Hardev Pandha,Agnieszka Michael, Andrzej Kierzek,on behalf of the PRACTICAL consortium; Jyotsna Batra, Judith A. Clements, on behalf of the Australian Prostate Cancer BioResource; Demetrius lbanes48, Gerald L. Andriole, Sonja I. Berndt, Stephen Chanock, Susan M. Gapstur, Edward L. Giovannucci,David J. Hunter, Peter Kraft, Loic Le Marchand, Jing Ma, Alison M. Mondul, Kathryn L. Penney, Meir J. Stampfer,Victoria L. Stevens, Stephanie J.Weinstein, Antonia Trichopoulou, Bas H. Bueno-de-Mesquita, Anne Tjønneland,David G. Cox, on behalf of the BPC3 consortium; Lovise Maehle, Johanna Schleutker, Sara Lindstr€om, and Fredrik Wiklund
Publication year: 2015
Journal: Cancer Epidemiology, Biomarkers and Prevention
Volume: 24
Issue: 11
First page : 1796
Last page: 1800
Number of pages: 5
ISSN: 1055-9965
DOI: https://doi.org/10.1158/1055-9965.EPI-15-0543
Background: Unnecessary intervention and overtreatment of
indolent disease are common challenges in clinical management
of prostate cancer. Improved tools to distinguish lethal from
indolent disease are critical.
Methods: We performed a genome-wide survival analysis of
cause-specific death in 24,023 prostate cancer patients (3,513
disease-specific deaths) from the PRACTICAL and BPC3 consortia.
Top findings were assessed for replication in a Norwegian
cohort (CONOR).
Results: We observed no significant association between genetic
variants and prostate cancer survival.
Conclusions: Common genetic variants with large
impact on prostate cancer survival were not observed in this
study.
Impact: Future studies should be designed for identification
of rare variants with large effect sizes or common variants
with small effect sizes.
